The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Illumina to Announce Second Quarter 2012 Results on Tuesday, July 24, 2012

Friday, July 13, 2012

Illumina to Announce Second Quarter 2012 Results on Tuesday, July 24, 201206:30 EDT Friday, July 13, 2012 SAN DIEGO (Business Wire) -- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for second quarter 2012 following the close of market on Tuesday, July 24, 2012. On the same day, at 2:00pm Pacific Time (5:00pm Eastern Time) Jay Flatley, President and Chief Executive Officer, Christian Henry, Senior Vice President and General Manager, Genomic Solutions, and Marc Stapley, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 2:00pm Pacific Time (5:00pm Eastern Time) on Tuesday, July 24, 2012. Interested parties may listen to the call by dialing 888.680.0890 (passcode: 97408950), or if outside North America, by dialing +1.617.213.4857 (passcode: 97408950). Individuals may access the live teleconference in the Investor Relations section of Illumina's web site under the “Company” tab at www.illumina.com. A replay of the conference call will be available from 4:00pm Pacific Time (7:00pm Eastern Time) on July 24, 2012 through July 31, 2012 by dialing 888.286.8010 (passcode: 51099189), or if outside North America, by dialing +1.617.801.6888 (passcode: 51099189). About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. Illumina, Inc.Investors:Kevin Williams, MD, Investor Relations858-332-4989kwilliams@illumina.comorMedia:Jennifer Temple, Public Relations858-246-8816pr@illumina.com